<DOC>
	<DOCNO>NCT00517491</DOCNO>
	<brief_summary>The purpose protocol evaluate correlation plasma lanreotide level Growth Hormone ( GH ) /Insulin Like Growth Factor 1 ( IGF-1 ) dynamic clinical improvement patient acromegaly treat lanreotide Autogel ( Somatuline ATG )</brief_summary>
	<brief_title>Study Evaluate Patients With Acromegaly Treated With Lanreotide Autogel ( Somatuline ATG )</brief_title>
	<detailed_description />
	<mesh_term>Acromegaly</mesh_term>
	<mesh_term>Lanreotide</mesh_term>
	<mesh_term>Angiopeptin</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<criteria>Patient treatment octreotide LAR 20 mg administer every 28 day least 3 month prior visit 1 . Patient must serum GH level ≤ 2.5 ng/mL serum IGF1 ≤ 1.3 ULN , 28 day last injection octreotide LAR 20 mg visit 1 . Patients must serum GH level &gt; 2.5 ng/mL AND serum IGF1 level &gt; 1.3 ULN , 6 8 week last injection octreotide LAR 20 mg . The patient receive pituitary radiation therapy kind time prior visit 1 . The patient receive pituitary surgery within 3 month prior visit 1 . The patient 's serum creatinine high 150 µmol/l .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2008</verification_date>
</DOC>